Elections for the interim
dividend in respect of the six months to December 31, 2016
February 24, 2017 - Shire
plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announced on
February 16, 2017, an interim
dividend of 25.70 US cents per Ordinary Share payable on
April 25, 2017, to shareholders on
the register of members at the close of business on
March 10, 2017.
Holders of Ordinary Shares are notified that, in order to
receive UK sourced dividends via the Company’s Income Access Share
arrangements (“IAS Arrangements”), they need to have submitted a
valid IAS Arrangements election form to the Company’s Registrar,
Equiniti, by no later than 5pm (GMT)
on March 24, 2017.
Holders of Ordinary Shares are advised that:
-
any previous elections made using versions of the IAS
Arrangements election form in use prior to February 16, 2016, and any elections deemed to
have been made prior to April 28,
2016, are no longer valid; and
-
if they do not elect, or have not elected using the newly
formatted IAS Arrangements election forms published on or after
February 16, 2016, to receive UK
sourced dividends via the Company’s IAS Arrangements, their
dividends will be Irish sourced and therefore incur Irish dividend
withholding tax, subject to applicable exemptions.
Internet links to the newly formatted IAS Arrangements election
forms can be found at:
http://investors.shire.com/shareholder-information/shareholder-forms.aspx
For further information concerning the IAS Arrangements, please
contact Equiniti (+44 (0) 121 415 7593). If you are in any doubt as
to what action to take, please consult your tax advisor
immediately.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please
contact:
Investor
Relations |
|
|
Ian Karp |
ikarp@shire.com |
+1 781
482 9018 |
Robert Coates |
rcoates@shire.com |
+44 1256
894874 |
Media |
|
|
Lisa Adler |
lisa.adler@shire.com |
+1 617
588 8607 |
Debbi Ford |
debbi.ford@shire.com |
+1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on
serving people with rare diseases. We strive to develop
best-in-class products, many of which are available in more than
100 countries, across core therapeutic areas including Hematology,
Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders,
Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live
their lives to the fullest.
www.shire.com